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Abstract
Introduction: The purpose of this study was to determine whether anti-tumour necrosis factor alpha (anti-TNF-a)
antibody, infliximab, can inhibit T helper 17 (Th17) differentiation in uveitis patients who have Behçet’s disease (BD).
Methods: To measure inflammatory cytokines, ocular fluid samples from BD patients being treated with infliximab
were collected. Cluster of differentiation 4 (CD4)+ T cells from BD patients with active uveitis were co-cultured with anti-
cluster of differentiation 3/cluster of differentiation 28 (CD3/CD28) antibodies in the presence of infliximab. For the
induction of Th17 cells, CD4+ T cells from BD patients were co-cultured with anti-CD3/CD28, anti-interferon-gamma
(anti-IFN-g), anti-interleukin-4 (anti-IL-4), and recombinant proteins such as interleukin-1 beta (IL-1b), interleukin-6 (IL-6),
interleukin-23 (IL-23), and TNF-a. The BD T cells were co-cultured with infliximab, and the production of interleukin-17
(IL-17) was evaluated by ELISA and flow cytometry, and the expression of retinoid-acid receptor-related orphan receptor
gamma t (RORgt) was also evaluated by flow cytometry. In addition, intraocular cells collected from mice with
experimental autoimmune uveitis (EAU) were used for the assay with anti-TNF-a blocking antibody.
Results: Ocular fluids from active uveitis patients who have BD contained significant amounts of inflammatory
cytokines such as IFN-g, IL-2, TNF-a, IL-6, and IL-17, while ocular fluids from infliximab patients did not contain any
inflammatory cytokines. Activated CD4+ T cells from BD patients produced large amounts of TNF-a and IL-17, whereas
T cells in the presence of infliximab failed to produce these cytokines. Polarized Th17 cell lines from BD patients
produced large amounts of IL-17, and Th17 cells exposed to infliximab had significantly reduced IL-17 production.
Polarized BD Th17 cells expressed large amounts of transcription factor RORgt. In contrast, in vitro-treated infliximab
Th17 cells expressed less RORgt. Moreover, intraocular T cells from EAU mice had a high population of IL-17+ cells, and
retinal antigen-specific T cells from EAU mice produced large amounts of IL-17 in the presence of retinal peptide.
However, the EAU T cells produced less IL-17 if the T cells were treated with anti-TNF-a antibody.
Conclusions: These results indicate that anti-TNF-a therapy suppresses effector T-cell differentiation in BD patients
with uveitis. Thus, suppression of effector T-cell differentiation by anti-TNF-a therapy may provide protection from
severe ocular inflammation in BD.
Introduction
Behçet’s disease (BD) is a serious sight-threatening clini-
cal entity of uveitis that can be accompanied by recurrent
oral aphthous ulcers, genital ulcers, and skin lesions.
Patients with BD have recurrent episodes of uveoretinitis,
which can cause irreversible damage to the neural retina
and optic nerve, leading to vision loss [1]. Tumor necro-
sis factor-alpha (TNF-a) is a proinflammatory cytokine
that plays a significant role in the immune response in
BD. Previous studies have suggested that BD is predomi-
nated by a T helper 1 (Th1) immune response. Increased
levels of Th1-associated cytokines, such as interferon-g
(IFN-g), interleukin-12 (IL-12), and TNF-a have been
found in BD patients [2,3]. Recently, several investigators
reported that active BD was characterized by increased
levels of IL-17 as compared to BD in remission or control
healthy donors [4-6]. Importantly, recent genetic surveys
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including genome-wide association studies (GWAS) have
identified IL23R-IL12RB2 and IL10 as BD susceptibility
loci, suggesting that BD is predominated by Th1/Th17-
type immune responses [7,8]. Therefore, Th17 cells, in
addition to Th1 cells, should be instrumental in the
pathogenesis of BD and uveitis.
A new anti-TNF-a monoclonal antibody, infliximab,
greatly suppresses ocular inflammation in uveitis patients
with BD [9-16]. The antibody neutralizes membrane-
bound TNF-a and soluble TNF-a and suppresses TNF-a
production by macrophages and lymphocytes. An alterna-
tive inhibition mechanism of infliximab is the promotion
of regulatory T cells that acquire suppressive functions in
the periphery including the eye [17]. Thus, infliximab is
extremely effective in the suppression of intraocular
inflammation in BD. However, the suppression mechan-
isms of infliximab remain unknown. We suspect that
other factor(s) are involved in the mechanisms.
The present study showed that the production of IL-17
by stimulated CD4+ T cells, which is associated with active
ocular inflammation in BD patients, is significantly ele-
vated in BD patients with active uveitis. In addition, the
production of IL-17 by polarized Th17 cell lines exposed
to infliximab in vitro or fresh CD4+ T cells from BD
patients being treated with infliximab was greatly reduced,
and the Th17 transcription factor RORgt in T cells was
also reduced. Moreover, TNF-a promoted Th17 differen-
tiation in BD CD4+ T cells. These data suggest that the
inhibition of Th17 differentiation by anti-TNF-a therapy
may protect BD patients from severe ocular inflammation.
Materials and methods
Subjects
Behçet’s disease (BD) was diagnosed based on the criteria
of the BD Research Committee of the Ministry of Health
and Welfare of Japan [18]. Subjects were uveitis patients
with BD at Tokyo Medical and Dental University Hospital
between 2009 and 2011. The subjects did not have severe
active systemic inflammation at the time of study partici-
pation. After informed consent was obtained, samples of
aqueous humor and vitreous fluid were collected from
patients with uveitis, either active (n = 6) or inactive (n =
4), associated with BD. At the time of aqueous humor
sampling, the uveitis patients had active intraocular
inflammation, but they were not being treated with sys-
temic therapy. In patients with uveitis who were under-
going vitreous surgery, vitreous fluid samples were
collected during the surgery. At the time of surgery, none
of the patients were receiving systemic corticosteroids, and
uveitis was active in two BD patients who developed ret-
inal detachment associated with a macular hole and inac-
tive in two patients who developed vitreous hemorrhages.
We also collected ocular fluid samples from BD patients
who were being treated with infliximab (all aqueous
humor, n = 8). The controls consisted of the aqueous
humor of patients with age-related cataracts (n = 3) and
the vitreous fluid of patients with idiopathic macular holes
(n = 3) obtained during surgery. These control patients
had no clinical history of uveitis or systemic diseases.
About 0.1 ml of aqueous humor was drawn into tuber-
culin syringes. After the aqueous humor samples were
centrifuged at 3000 rpm for five minutes and the vitreous
fluid (about 0.5 ml) was centrifuged at 10000 rpm for five
minutes, the supernatants were collected and stored in
separate tubes at -80°C until use. The research followed
the tenets of the Declaration of Helsinki, and the study
was approved by the Institutional Ethics Committees of
Tokyo Medical and Dental University.
Isolation of purified T cells and induction of Th17 cell
lines
Peripheral blood mononuclear cells (PBMCs) were
obtained from the BD patients or a sarcoidosis patient
(control) with active uveitis and healthy donors. Freshly
purified T cells were enriched for CD4+ cells using
MACS cell isolation kits (Miltenyi Biotec, Auburn, CA,
USA > 93% CD4+) and applied to flow cytometric analy-
sis or in vitro assays.
For the induction of human Th17 cells, purified CD4+
T cells from BD patients or healthy donors were co-cul-
tured with anti-human CD3 antibody (2 μg/ml, BD Phar-
Mingen, San Diego, CA, USA), anti-human CD28
antibody (2 μg/ml, BD PharMingen), anti-human IFN-g
antibody (5 μg/ml, R&D Systems, Minneapolis, MN,
USA), anti-human IL-4 antibody (5 μg/ml, R&D Sys-
tems), and recombinant human proteins such as IL-1b
(20 ng/ml, Peprotech, Rocky Hill, NJ, USA), IL-6 (20 ng/
ml, R&D Systems), IL-23 (20 ng/ml, R&D Systems), and
TNF-a (20 ng/ml, R&D Systems). After five days of cul-
ture, the harvested T cells that produced large amounts
of IL-17 were used for assays.
ELISA or cytometric beads array (CBA) assay for cytokines
Purified CD4+ T cells were co-cultured with recombi-
nant human IL-2 (100 U/ml), anti-human CD3 antibody
(2 μg/ml), and anti-human CD28 antibody (2 μg/ml) in
the presence (or absence) of infliximab (10 μg/ml) for
48 hours. As the control antibodies (Abs) for infliximab,
anti-human TNF-a Abs (10 μg/ml, R&D Systems) and
anti-human IL-6 monoclonal Abs (10 μg/ml, R&D Sys-
tems) were also used.
The concentration of cytokines in supernatants of the
T-cell cultures (stimulated T cells in the presence of inflix-
imab) was measured by a CBA assay kit that included IL-4,
IL-6, IL-10, TNF-a, or IFN-g. The assay was performed
according to the manufacturer’s instructions (Human
Th1/Th2 Cytokine Kit, BD PharMingen). The concentra-
tion of IL-17 (R&D Systems) in the supernatants of the
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T-cell cultures was also measured by ELISA. Collected
ocular fluids (aqueous humor or vitreous fluids) from
uveitis patients (active uveitis, inactive uveitis without
treatment, or infliximab treatment) and controls were also
measured by CBA (IL-2, IL-4, IL-6, IL-10, TNF-a, and
IFN-g) or ELISA (IL-17).
Flow cytometric analysis
Flow cytometric analysis of Th17 cell lines derived
from BD patients or healthy donors was performed
using phycoerythrin (PE)-labeled anti-human IL-17
monoclonal antibodies (R&D Systems). T cells were
pre-cultured with GolgiPlug (BD Biosciences, San Jose,
CA, USA), ionomycin (0.5 μg/ml; Sigma-Aldrich Co.,
St. Louis, MO, USA), and phorbol-12-myristate-13-
acetate (PMA, 40 ng/ml; Merck Chemical, Darmstadt,
Germany) for five hours before intracellular staining.
After permeabilization, Th17 cells were stained with
PE-labeled anti-human IL-17 antibodies and fluorescein
isothiocyanate (FITC)-labeled anti-human CD4 Abs.
PE-conjugated goat immunoglobulin G (IgG; R&D Sys-
tems) was used as the isotype control. Cells (1 × 106)
were stained for 40 minutes at room temperature in
the dark. These T cells, Th17 cells and infliximab-
exposed Th17 cells were also stained with PE-labeled
anti-human RORgt abs (eBioscience, San Diego, CA,
USA) and FITC-labeled anti-human CD4 Abs. Fresh
CD4 T cells from an active BD patient, a BD patient
with infliximab treatment, and a healthy donor were
also stained with anti-human RORgt Abs. PE-conju-
gated rat IgG (eBioscience) was used as the isotype
control. After permeabilization, cells (1 × 106) were
stained for 30 minutes at 4°C in the dark.
Induction of experimental autoimmune uveitis (EAU) in
mice and use of spleen cells and intraocular cells
Normal mice were subcutaneously immunized in the neck
with 200 μg of interphotoreceptor retinoid-binding protein
peptide (IRBP1-20) emulsified in complete Freund’s adju-
vant (Difco, Detroit, MI, USA) and containing Mycobac-
terium tuberculosis strain H37Ra (Difco), as previously
described [19]. Funduscopic examinations were performed
on days 14 and 21, as previously described [20-22]. Inflam-
mation was evaluated based on the fundus findings, and
spleen cells and intraocular cells were used for in vitro
assays.
Statistical evaluation
Each experiment was repeated at least twice with similar
results. Parametric data were analyzed with the Stu-
dent’s t test. Nonparametric data were analyzed with the
Mann-Whitney U test. Values were considered statisti-
cally significant at P < 0.05.
Results
Levels of cytokines in ocular fluids from uveitis patients
with Behçet’s disease during infliximab treatment
We first tested whether ocular fluids from patients with
Behçet’s disease (BD) accompanied by refractory uveitis
contained inflammatory cytokines and if these cytokine
levels decreased after infliximab treatment. Ocular fluids
(aqueous humor or vitreous fluids) were collected from
BD patients who had active uveitis, BD patients who had
inactive uveitis at the remission stage without treatment,
and BD patients who were being treated with infliximab.
The control samples were aqueous humor from patients
with age-related cataracts and vitreous fluids from
patients with idiopathic macular holes. The ocular fluids
from BD patients with active uveitis contained significant
amounts of inflammatory cytokines, such as IFN-g, IL-2,
TNF-a, IL-6, and IL-17 (Figure 1). The levels of these
cytokines in ocular fluids from BD patients with inactive
uveitis were very low or undetectable (Figure 1). Ocular
fluids from the control subjects and from BD patients
who were being treated with infliximab did not contain
any inflammatory cytokines (Figure 1). There were statis-
tically significant differences between the cytokine levels
of the active uveitis group and the infliximab group. Th2-
type cytokines (IL-4 and IL-10) were undetectable in all
samples (Figure 1). These results imply that ocular-infil-
trating inflammatory cells in BD patients who have active
uveitis may produce inflammatory cytokines. However,
the inflammatory cytokines in ocular fluid completely
disappeared after infliximab treatment.
In vitro effects of infliximab on T cells from uveitis
patients with Behçet’s disease
CD4+ T cells from BD patients with active uveitis were
co-cultured with rIL-2, anti-human CD3 Ab, and anti-
human CD28 Ab in the presence of infliximab for 48
hours. Conventional anti-human TNF-a and anti-
human IL-6 monoclonal antibodies were used as posi-
tive and negative control Abs, respectively, for inflixi-
mab. As revealed in Figure 2, the activated CD4+ T cells
from BD patients produced large amounts of IFN-g
(Figure 2A), TNF-a (Figure 2D), IL-6 (Figure 2E), and
IL-17 (Figure 2F) as compared to the CD4+ T cells from
healthy donors. The T cells from BD patients produced
lower levels of Th2-type cytokines such as IL-4 (Figure
2B) and IL-10 (Figure 2C) as compared to T cells from
control subjects.
As expected, the BD T cells produced large amounts of
TNF-a as compared to T cells from healthy donors,
whereas T cells in the presence of infliximab or conven-
tional anti-human TNF-a monoclonal Abs failed to
produce TNF-a (Figure 2D). By contrast, control Ab
(anti-IL-6) had no effect on TNF-a production. Similarly,
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activated CD4+ T cells from healthy donors produced
less TNF-a after in vitro treatment with infliximab
(Figure 2D). Thus, infliximab, which is a chimeric
antibody against human TNF-a, neutralized TNF-a-
producing activated T cells.
The amount of IL-6 produced by activated T cells in the
presence of infliximab or anti-TNF-a control Ab was sig-
nificantly reduced (Figure 2E). Moreover, these activated
T cells treated with anti-IL-6 monoclonal antibodies failed
to produce IL-6 (Figure 2E). There are similar results for
the Th1 cytokine IFN-g and the Th17 cytokine IL-17. The
levels of IFN-g (Figure 2A) and IL-17 (Figure 2F) produced
by BD T cells in the presence of infliximab or anti-TNF-a
control Ab were significantly reduced. The low levels of
Th2-type cytokines, such as IL-4 (Figure 2B) and IL-10
(Figure 2C), produced by activated T cells were unchanged
after infliximab treatment. Taken together, these results
suggest that TNF-a may function as a proinflammatory
cytokine in BD and that the levels of other inflammatory
cytokines (for example, IL-6, IFN-g, and IL-17) are
reduced if TNF-a is blocked.
Induction of IL-17-producing T cells from uveitis patients
with Behçet’s disease
Th17 cells are IL-17-producing CD4+ T cells that are a
unique subset of Th cells that develop along a pathway
distinct from the Th1 and Th2 cell differentiation path-
ways [23-25]. IL-17 is an inflammatory cytokine that
promotes inflammatory responses and correlates with
autoimmune disorders, including eye disorders [26,27]
and BD [4-6]. In addition, Th17 cells play an important
role in the pathogenesis of experimental autoimmune
uveitis, which is an animal model of BD [28-30]. We
next confirmed that CD4+ T cells from BD patients
convert into Th17 cells after the addition of Th17 dif-
ferentiation factors. For the assay, we established polar-
ized Th17-type cells by culturing purified CD4+ T cells
in the presence of anti-human CD3 antibody, anti-
human CD28 antibody, anti-human IFN-g antibody,
anti-human IL-4 antibody, recombinant IL-1b, recom-
binant IL-6, recombinant IL-23, and recombinant
TNF-a.
T cells from an active uveitis patient with sarcoidosis
(disease control) and a healthy donor were used as con-
trols. Compared with conventional CD4+ T cell lines
that were co-cultured with anti-CD3 and anti-CD28
antibodies, polarized Th17 cells from both a BD patient,
a sarcoidosis patient, and a healthy donor produced
large amounts of IL-17, particularly BD T cells, as deter-
mined by ELISA (Figure 3A). Similarly, significant IL-17
production by BD CD4+ T cells was shown by flow
cytometric analysis (IL-17/CD4 double-positive cells,
Figure 1 Cytokine concentrations in ocular fluids from uveitis patients with Behçet’s disease during infliximab treatment. The levels of
cytokines such as IFN-g, IL-2, IL-4, IL-10, TNF-a, IL-6, and IL-17 were evaluated by ELISA or CBA. Ocular fluid samples from patients who had
Behçet’s disease (BD) with active uveitis (n = 6) or inactive uveitis (n = 4; no signs or symptoms of uveitis at the remission stage without
treatment) were used for the assay. We also collected ocular fluid samples from BD patients receiving infliximab (IFX, n = 8). The controls
consisted of the aqueous humor of patients with age-related cataracts (n = 3) and the vitreous fluid of patients with idiopathic macular holes (n
= 3). P value indicates active uveitis group (active UVE) vs. infliximab group (IFX treatment). CBA, cytometric beads array; n.s., not significant.
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Figure 2 In vitro effects of infliximab on CD4+ T cells from uveitis patients with Behçet’s disease. CD4+ T cells from Behçet’s disease (BD)
patients (black bars) with active uveitis or healthy donors (HD, open bars) were co-cultured with rIL-2 and anti-human CD3/CD28 abs in the
presence of infliximab (IFX). As the control abs for infliximab, anti-human TNF-a monoclonal antibody (aTNF-a) or anti-human IL-6 monoclonal
antibody (aIL-6) were used. The levels of cytokines such as IFN-g (A), IL-4 (B), IL-10 (C), TNF-a (D), IL-6 (E), and IL-17 (F) in supernatants of T cells
were evaluated by ELISA or CBA. Bars, mean ± SEM. Cytokine production by T cells. Asterisks mean values significantly higher than medium only
(Abs (-)): *P < 0.05, **P < 0.005, ***P < 0.0005. Abs, antibodies; CBA, cytometric beads array; n.s., not significant; SEM, standard error of the mean.
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77%: Figure 3B). These results suggest that IL-17 may
promote inflammatory responses and correlate with BD.
Capacity of infliximab to suppress polarized Th17 cells
from uveitis patients with Behçet’s disease
We next examined whether infliximab-treated T cells
from BD patients can suppress the production of IL-17
cytokines in vitro. For this assay, we induced Th17 cell
lines as described above. CD4+ Th17-type cells from a
BD patient, a sarcoidosis patient, and a healthy donor sig-
nificantly suppressed IL-17 production after exposure to
infliximab (Figure 4A). We next confirmed that recombi-
nant TNF-a could promote Th17 induction in BD
patients who have active uveitis. As expected, Th17 cell
lines from BD patients exposed to recombinant TNF-a
significantly upregulated IL-17 production by T cells in a
dose-dependent manner (Figure 4B). Similarly, Th17
cells induced from a sarcoidosis uveitis patient upregu-
lated the IL-17 production when recombinant TNF-a
was added to cultures (data not shown), suggesting that
TNF-a may be generally essential for Th17 differentia-
tion in inflammatory diseases.
Next, we determined whether TNF-a can convert CD4+
T cells into Th17 cells in animal models. For the murine
assay, we induced Th17 cells by culturing purified splenic
CD4+ T cells in the presence of anti-mouse CD3 antibody,
anti-mouse CD28 antibody, anti-mouse IFN-g antibody,
anti-mouse IL-4 antibody, recombinant IL-6, recombinant
TGFb, and recombinant TNF-a. Murine Th17 cells pro-
duced large amounts of IL-17, as determined by flow
Figure 3 Establishment of IL-17-producing Th17 cells from uveitis patients with Behçet’s disease. (A) Purified CD4+ T cells from a
Behçet’s disease (BD) patient or a sarcoidosis (SAR) patient (black bars) with active uveitis or a healthy donor (HD, open bars) in the presence of
anti-CD3/CD28 antibodies, anti-IFN-g antibody, anti-IL-4 antibody, rIL-1b, rIL-6, rIL-23, and rTNF-a. For ELISA analysis, supernatants of polarized
Th17 cell lines or control CD4+ T cell lines in the presence of only anti-CD3/CD28 antibodies were harvested. The graph indicates the amount of
IL-17 determined by ELISA (pg/ml). (B) For flow cytometric analysis, harvested Th17 cell lines from BD or HD were stained with anti-IL-17 abs
and anti-CD4 Abs after permeabilization. The numbers in the histograms indicate the percentages of cells that were double-positive for IL-17/
CD4. Abs, antibodies.
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Figure 4 Capacity of infliximab to inhibit Th17 cells from uveitis patients with Behçet’s disease. (A) For ELISA analysis, polarized Th17 cell lines
from a Behçet’s disease (BD) patient (black bars) were co-cultured with infliximab (IFX). As controls, T cells from a sarcoidosis patient (SAR, black bars)
and a healthy donor (HD, open bars) were exposed to IFX. The graph indicates the amount of IL-17 determined by ELISA (pg/ml). *P < 0.05, **P <
0.005 between two groups. (B) The polarized Th17 cell lines from BD were co-cultured with recombinant human TNF-a (5, 50, and 500 ng/ml), and
then the supernatants were harvested to evaluate IL-17 production by ELISA (pg/ml). **P < 0.005, compared with control data without rTNF-a (open
bar). (C) For flow cytometric analysis, murine Th17 cell lines induced from a spleen of a normal C57BL/6 mouse were stained with anti-mouse IL-17
abs and anti-mouse CD4 Abs after permeabilization. The lower histogram indicates mouse Th17 cell lines co-cultured with rTNF-a. The numbers in the
histograms indicate the percentages of cells that were double-positive for IL-17/CD4. Right panel: The mouse Th17 cell lines were co-cultured with
recombinant mouse TNF-a (5, 50, and 500 ng/ml), and then the supernatants were harvested to evaluate IL-17 production by ELISA (ng/ml). *P < 0.05,
**P < 0.005, ***P < 0.0005, compared with control data without rTNF-a (open bar). Abs, antibodies.
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cytometric analysis (Figure 4C). Moreover, murine Th17
cells in the presence of recombinant mouse TNF-a pro-
duced large amounts of IL-17 (Figure 4C). We obtained
similar results by ELISA. Compared with murine Th17
cells without rTNF-a, the Th17 cells in the presence of
rTNF-a produced greater amounts of IL-17 (right panel in
Figure 4C). These results indicate that proinflammatory
cytokine TNF-a can promote Th17 differentiation.
Expression of Th17 transcription factors in T cells from
uveitis patients with Behçet’s disease
Retinoid-acid receptor-related orphan receptor gamma t
(RORgt) is one of several transcription factors involved in
the differentiation of Th17 cells [31,32]. By flow cytometric
analysis, fresh CD4 T cells from a uveitis patient with BD-
expressed RORgt (middle histogram in Figure 5A) at a
high level as compared to CD4 T cells from a healthy
donor (left histogram in Figure 5A). In contrast, fresh T
cells from a BD patient treated with infliximab expressed
RORgt at a low level (right histogram in Figure 5A).
Similarly, polarized Th17 cell lines from a BD patient
expressed high levels of RORgt (middle histogram in Figure
5B). By contrast, in vitro-treated infliximab Th17 cells sup-
pressed RORgt expression (right histogram in Figure 5B).
These results suggest that an anti-TNF-a blockade may
prevent the differentiation of Th17 cells.
Detection of Th17 cells in experimental autoimmune
uveitis (EAU) and effect of anti-TNF-a blockade against
murine Th17 cells
Normal mice were immunized with interphotoreceptor
retinoid-binding protein peptide (IRBP) to induce EAU.
On day 21 after immunization, mice were sacrificed and
spleen cells and intraocular cells were collected. As
expected, the spleens and eyes from EAU donors con-
tained significant numbers of CD4+IL-17+ Th17-type T
cells (Figure 6A). By contrast, fresh splenic CD4+ T cells
from normal non-immunized mice had only a small popu-
lation of IL-17+ cells (Figure 6A). Next, we examined if
intraocular T cells from EAU donors can produce IL-17 in
Figure 5 Expression of Th17 transcription factors RORgt in T cells from uveitis patients with Behçet’s disease. (A) By flow cytometric
analysis, fresh CD4 T cells from an active uveitis patient with Behçet’s disease (BD) (middle histogram), an inactive uveitis patient treated with
infliximab (IFX-treated BD: right histogram), or a healthy donor (HD: left histogram) were stained with anti-RORgt Abs and anti-CD4 Abs. (B) Th17
cell lines from the active uveitis patient with BD were co-cultured with infliximab and then stained with anti-RORgt Abs. The numbers in the
histograms indicate the percentages of cells that were double-positive for RORgt/CD4. Abs, antibodies; RORgt, retinoid-acid receptor-related
orphan receptor gamma t.
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the presence of IRBP peptide plus anti-TNF-a blocking
antibody. T cells from EAU donors produced large
amounts of IL-17 in the presence of IRBP peptide in vitro
(Figure 6B). However, the IRBP retinal antigen-specific T
cells failed to produce IL-17 if they were treated with anti-
mouse TNF-a blocking antibody (Figure 6B). These
results suggest that anti-TNF-a blockade may prevent the
differentiation of Th17 cells in animal models for BD. In
fact, the administration of anti-TNF-a protects EAU
donors from intraocular inflammation [33].
Discussion
In the present study, we showed that ocular fluids from
BD patients who have active uveitis contained significant
amounts of inflammatory cytokines including TNF-a,
whereas ocular fluids from patients being treated with
infliximab as well as ocular fluids from control nonin-
flammatory patients did not contain any inflammatory
cytokines. Moreover, ocular fluids from BD patients who
have active uveitis contained significant amounts of
inflammatory cytokine IL-17. The levels of IL-17 in ocu-
lar fluids from inactive uveitis patients were very low or
undetectable, and ocular fluids from patients who were
being treated with infliximab as well as ocular fluids from
control noninflammatory patients did not contain inflam-
matory cytokines. Activated CD4+ T cells obtained from
BD patients produced large amounts of TNF-a in vitro,
whereas T cells in the presence of infliximab did not pro-
duce inflammatory cytokines. Thus, infliximab, which is
a chimeric antibody against human TNF-a, neutralized
Figure 6 Detection of Th17 cells in experimental autoimmune uveitis (EAU) donors. Normal mice (n = 20) were immunized with IRBP1-20.
The spleen cells (n = 1) and intraocular cells (n = 10) were collected from EAU donors. (A) By flow cytometric analysis, fresh cells from EAU eyes
(upper histogram), fresh cells from EAU spleen (middle histogram), and fresh cells from the spleen of a normal mouse (lower histogram) were
stained with anti-mouse IL-17 abs and anti-mouse CD4 Abs after permeabilization. The numbers in the histograms indicate the percentages of
cells that were double-positive for IL-17/CD4. (B) The intraocular T cells were collected from EAU eyes (n = 10) and evaluated by the IRBP retinal
antigen-specific assay. The EAU T cells (1 × 105/well) were co-cultured with anti-TNF-a antibody (1 μg/ml) in the presence of antigen-presenting
cells (20 Gy x-irradiated spleen cells: 1 × 104/well) plus mouse IRBP peptide (10 μg/ml) for 48 hours. As a control, T cells were prepared in the
absence of peptide and antibody (T cells alone). ELISA was used to measure the IL-17 cytokine concentration in the supernatants of the T-cell
cultures. **P < 0.005, between two groups. Abs, antibodies; IRBP, interphotoreceptor retinoid-binding protein.
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TNF-a-producing cells. We also demonstrated that CD4+
T cells exposed to infliximab in vitro failed to produce
IL-17, suggesting that TNF-a is required for Th17 differ-
entiation in BD. To confirm this result, both human and
mouse recombinant TNF-a proteins were used. CD4+
BD T cells exposed to rTNF-a in vitro promoted IL-17
production, and murine Th17 cells greatly expressed
intracellular IL-17 when the T cells were co-cultured
with mouse rTNF-a. In addition, fresh T cells from a
uveitis patient with BD expressed high levels of the
RORgt transcription factor, whereas fresh T cells from a
patient being treated with infliximab expressed low levels
of RORgt. Similarly, Th17 cell lines from a BD uveitis
patient expressed high levels of the Th17-related tran-
scription factor. In contrast, the expression of RORgt was
suppressed in Th17 cells cultured with infliximab. These
results suggest that anti-TNF-a blockade may prevent
the differentiation of Th17 cells. We suspect that these
CD4+ T cells exposed to infliximab may convert into
T regulatory (Treg) cells, as described in our previous
report [17]. In fact, CD4+ T cells can convert into Th17
cells in the presence of IL-6 and TGFb, but the CD4+ T
cells can also convert into Treg cells through the TGFb
signal in the absence of IL-6 [23,34].
As well as soluble TNF-a. infliximab neutralizes mem-
brane-binding TNF-a in addition to suppressing TNF-a
production by antigen-presenting cells. When infliximab
has been used to treat patients with active rheumatoid
arthritis, the population of Treg cells that express forkhead
box P3 (Foxp3) has increased [35,36]. We previously
found that infliximab-induced Treg cells inducibly express
Foxp3 through the TGFb signal and that the Treg cells
may provide protection from the inflammatory conditions,
which is consistent with the results of Nadkarni et al. [36].
Importantly, infliximab-induced Treg cells from BD
patients suppressed the activation of target T cells.
The infliximab-induced Treg cells produced significant
amounts of TGFb1. Thus, peripherally induced Treg cells
may work as an alternative inhibition mechanism for
infliximab. It is assumed that treatment with anti-TNF-a
antibody promotes the conversion of inflammatory Th17
cells (RORgt+) to Treg cells (Foxp3+) to establish homeos-
tasis in BD patients. In other words, the Th17/Treg bal-
ance might be important for the pathogenesis of
inflammation in BD, as recently reported by Hamzaoui
et al. [37,38].
TNF-a, which functions as a proinflammatory cytokine,
is greatly involved in the aggravation of BD, particularly
the ocular symptoms [39-41]. TNF-a and other proinflam-
matory cytokines are produced by monocytes [39] and T
lymphocytes [40] in BD uveitis patients, and these inflam-
matory cytokines are critical for the formation of inflam-
matory lesions, such as ocular lesions. As shown in the
current experiments, infliximab significantly suppressed
IFN-g, IL-6 and IL-17 inflammatory cytokines in addition
to TNF-a produced by activated CD4+ T cells from BD
patients who have active uveitis. Ocular fluids from BD
patients being treated with infliximab did not contain
these inflammatory cytokines. These results imply that
Th1/Th17 cells, which play a significant role in the
immune responses in BD, may disappear in the peripheral
lesions including ocular lesions after infliximab therapy.
Th17 cells constitute a third subset of effector helper T
cells. The effector functions of Th17 cells are distinct from
those of Th1 and Th2 cells [23,24]. Th17 cells and IL-17
play a critical role in the pathogenic mechanisms of intrao-
cular inflammation in an animal model of human uveitis
in BD [28-30] as well as human uveitis [26,27]. Anti-
mouse IL-17-blocking antibodies [42] as well as anti-TNF-
a antibody [33] suppress intraocular inflammation in
experimental uveitis models. In the present study, we
showed that fresh intraocular T cells from immunized
EAU donors had a large population of IL-17+ cells, sug-
gesting that CD4+IL-17+ Th17-type T cells may be asso-
ciated with the pathogenic mechanisms of intraocular
inflammation. We also showed that retinal antigen-specific
CD4+ T cells from EAU produced large amounts of IL-17
in the presence of retinal peptide. Importantly, retinal anti-
gen-specific CD4+ EAU T cells produced less IL-17 if the
T cells were treated with anti-TNF-a blocking antibody.
Thus, anti-TNF-a blockade provides protection from
intraocular inflammation by Th17-type helper T cells in
animal models of BD.
Recently, several investigators reported that active BD
was characterized by increased levels of IL-17 as compared
to BD in remission or control healthy donors [4-6]. Chi et
al. reported that IL-23 mRNA in PBMCs, IL-23 in serum,
and IL-17 production in supernatants of PBMCs were all
markedly increased in BD patients who have active uveitis
[6]. Significantly upregulated IL-17-producing T cells were
also found in BD patients. They concluded that IL-23 and
IL-17 are associated with active ocular inflammation in
BD patients. Recent genetic surveys including GWAS have
identified IL23R-IL12RB2 and IL10 as BD susceptibility
loci [7,8]. These recent reports suggest that BD including
ocular inflammation is predominated by Th1/Th17-type
immune responses. Thus, blocking Th17 differentiation
may be a very important treatment strategy in BD.
Conclusions
The proinflammatory cytokine TNF-a can promote Th17
differentiation in BD patients who have uveitis. Anti-TNF-
a therapy, infliximab, is able to suppress Th17 differentia-
tion. T cells treated with infliximab fail to acquire the
effector T-cell function since the T cells did not produce
inflammatory cytokines and the expression of Th17 tran-
scription factor was significantly diminished. Thus, sup-
pression of effector T-cell differentiation by anti-TNF-a
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therapy may protect uveitis patients from severe ocular
inflammation.
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